These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29949016)

  • 1. A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.
    Pereira MJ; Lundkvist P; Kamble PG; Lau J; Martins JG; Sjöström CD; Schnecke V; Walentinsson A; Johnsson E; Eriksson JW
    Diabetes Ther; 2018 Aug; 9(4):1511-1532. PubMed ID: 29949016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of glucagon-like peptide-1 receptor agonist combined with sodium-glucose co-transporter-2 inhibitor in the treatment of type 2 diabetes mellitus patients with obesity: a retrospective analysis study.
    Wang J; Chen Y; Lu Y; Wang H; Zhao Y
    Am J Transl Res; 2023; 15(4):2949-2956. PubMed ID: 37193156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
    Ferrannini E; Baldi S; Frías JP; Guja C; Hardy E; Repetto E; Jabbour SA; DeFronzo RA
    Diabetes Obes Metab; 2020 Jan; 22(1):99-106. PubMed ID: 31469220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
    Elkind-Hirsch KE; Chappell N; Seidemann E; Storment J; Bellanger D
    J Clin Endocrinol Metab; 2021 Sep; 106(10):3019-3033. PubMed ID: 34097062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
    Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
    Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial.
    Harreiter J; Just I; Leutner M; Bastian M; Brath H; Schelkshorn C; Klepochova R; Krššák M; Kautzky-Willer A
    Diabetes Obes Metab; 2021 May; 23(5):1129-1139. PubMed ID: 33464703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
    Lundkvist P; Sjöström CD; Amini S; Pereira MJ; Johnsson E; Eriksson JW
    Diabetes Obes Metab; 2017 Jan; 19(1):49-60. PubMed ID: 27550386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A
    Brown E; Wilton MM; Sprung VS; Harrold JA; Halford JCG; Stancak A; Burgess M; Howarth E; Umpleby AM; Kemp GJ; Wilding JP; Cuthbertson DJ
    BMJ Open; 2021 Jul; 11(7):e045663. PubMed ID: 34285005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes.
    Cersosimo E; Alatrach M; Solis-Herrera C; Baskoy G; Adams J; Hansis-Diarte A; Gastaldelli A; Chavez A; Triplitt C; DeFronzo RA
    J Clin Endocrinol Metab; 2023 Dec; 109(1):161-170. PubMed ID: 37481263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity.
    Roth CL; Perez FA; Whitlock KB; Elfers C; Yanovski JA; Shoemaker AH; Abuzzahab MJ
    Diabetes Obes Metab; 2021 Feb; 23(2):363-373. PubMed ID: 33026160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
    Daniele G; Tura A; Brocchi A; Saba A; Campi B; Sancho-Bornez V; Dardano A; Del Prato S
    Diabetes Care; 2024 Jul; 47(7):1131-1139. PubMed ID: 38652656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
    Aroda VR; DeYoung MB
    Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.
    van Ruiten CC; Veltman DJ; Wijdeveld M; Ten Kulve JS; Kramer MHH; Nieuwdorp M; IJzerman RG
    Diabetes Obes Metab; 2022 Aug; 24(8):1588-1597. PubMed ID: 35491524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.
    Weghuber D; Forslund A; Ahlström H; Alderborn A; Bergström K; Brunner S; Cadamuro J; Ciba I; Dahlbom M; Heu V; Hofmann J; Kristinsson H; Kullberg J; Ladinger A; Lagler FB; Lidström M; Manell H; Meirik M; Mörwald K; Roomp K; Schneider R; Vilén H; Widhalm K; Zsoldos F; Bergsten P
    Pediatr Obes; 2020 Jul; 15(7):e12624. PubMed ID: 32062862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
    Alatrach M; Agyin C; Solis-Herrera C; Lavryneko O; Adams J; Gastaldelli A; Triplitt C; DeFronzo RA; Cersosimo E
    Diabetes Care; 2022 Jun; 45(6):1372-1380. PubMed ID: 35235659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
    Wang J; Jin X; An P; Yu S; Mu Y
    J Diabetes Res; 2019; 2019():8083417. PubMed ID: 31772945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.
    van Ruiten CC; van der Aart-van der Beek AB; IJzerman RG; Nieuwdorp M; Hoogenberg K; van Raalte DH; Heerspink HJL
    Diabetes Obes Metab; 2021 Aug; 23(8):1851-1858. PubMed ID: 33908691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity.
    Perez FA; Elfers C; Yanovski JA; Shoemaker AH; Abuzzahab MJ; Roth CL
    Diabetes Obes Metab; 2021 Jul; 23(7):1532-1541. PubMed ID: 33651438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy.
    Hansen L; Iqbal N; Ekholm E; Cook W; Hirshberg B
    Endocr Pract; 2014 Nov; 20(11):1187-97. PubMed ID: 25370334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
    Gastaldelli A; Nauck MA; Balena R
    Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.